CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.34B
This Quarter Return
+66.58%
1 Year Return
+85.27%
3 Year Return
+2,244.39%
5 Year Return
+2,846.94%
10 Year Return
+51,155.97%
AUM
$1.82B
AUM Growth
+$1.82B
(-3.4%)
Cap. Flow
+$20.8M
Cap. Flow
% of AUM
1.14%
Top 10 Holdings %
Top 10 Hldgs %
65.19%
Holding
53
New
8
Increased
7
Reduced
11
Closed
5
Top Buys
| 1 |
Praxis Precision Medicines
PRAX
|
$63.4M |
| 2 |
Janux Therapeutics
JANX
|
$56.2M |
| 3 |
DRUG
Bright Minds Biosciences
DRUG
|
$38.2M |
| 4 |
NewAmsterdam Pharma
NAMS
|
$20M |
| 5 |
OKUR
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
|
$15.8M |
Top Sells
| 1 |
LBPH
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
|
$93M |
| 2 |
Vaxcyte
PCVX
|
$47.1M |
| 3 |
UroGen Pharma
URGN
|
$13.3M |
| 4 |
Biohaven
BHVN
|
$12.9M |
| 5 |
AnaptysBio
ANAB
|
$11.5M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
MoonLake Immunotherapeutics
MLTX
$3.54B
| $460M | 25.26% | 8,494,151 | – | – |
|
|
2
Praxis Precision Medicines
PRAX
$958M
| $130M | 7.16% | 1,693,219 +823,219 | +95% | +$63.4M |
|
|
3
Janux Therapeutics
JANX
$1.37B
| $112M | 6.17% | 2,100,000 +1,050,000 | +100% | +$56.2M |
|
4
Arcellx
ACLX
$3.85B
| $99.7M | 5.48% | 1,300,000 +50,000 | +4% | +$3.83M |
|
5
Edgewise Therapeutics
EWTX
$1.51B
| $91M | 5% | 3,406,534 | – | – |
|
|
6
NewAmsterdam Pharma
NAMS
$2.71B
| $83.5M | 4.59% | 3,250,000 +780,000 | +32% | +$20M |
|
7
EyePoint Pharmaceuticals
EYPT
$797M
| $62M | 3.41% | 8,325,000 | – | – |
|
|
RAPP
8
Rapport Therapeutics
RAPP
$643M
| $52.2M | 2.87% | 2,940,921 | – | – |
|
9
Crinetics Pharmaceuticals
CRNX
$2.92B
| $51.1M | 2.81% | 1,000,000 -100,000 | -9% | -$5.11M |
|
10
Insmed
INSM
$28.8B
| $44.9M | 2.46% | 650,000 +150,000 | +30% | +$10.4M |
|
11
BridgeBio Pharma
BBIO
$9.89B
| $43.9M | 2.41% | 1,600,000 -258,351 | -14% | -$7.09M |
|
|
CNTA
12
Centessa Pharmaceuticals
CNTA
$2.25B
| $42.9M | 2.36% | 2,561,600 | – | – |
|
|
DRUG
13
Bright Minds Biosciences
DRUG
$276M
| $38.2M | 2.1% | +1,059,331 | New | +$38.2M |
|
|
14
Vaxcyte
PCVX
$4B
| $34.8M | 1.91% | 425,000 -575,000 | -58% | -$47.1M |
|
15
Merus
MRUS
$4.98B
| $31.1M | 1.71% | 740,000 | – | – |
|
|
BBOT
16
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $30.5M | 1.68% | 2,909,000 | – | – |
|
17
Avidity Biosciences
RNA
$5.99B
| $30.5M | 1.68% | 1,050,000 | – | – |
|
18
Pharvaris
PHVS
$1.39B
| $28.1M | 1.54% | 1,466,460 | – | – |
|
19
Corbus Pharmaceuticals
CRBP
$115M
| $28M | 1.54% | 2,375,000 | – | – |
|
20
Tarsus Pharmaceuticals
TARS
$2.47B
| $27.7M | 1.52% | 500,000 | – | – |
|
21
Axsome Therapeutics
AXSM
$6.05B
| $27.5M | 1.51% | 325,000 -75,000 | -19% | -$6.35M |
|
22
Arcutis Biotherapeutics
ARQT
$1.86B
| $25.4M | 1.4% | 1,825,000 -500,000 | -22% | -$6.97M |
|
23
Rhythm Pharmaceuticals
RYTM
$6.85B
| $22.4M | 1.23% | 400,000 | – | – |
|
24
CG Oncology
CGON
$2.04B
| $22.2M | 1.22% | 775,000 -200,000 | -21% | -$5.74M |
|
|
CRGX
25
DELISTED
CARGO Therapeutics
CRGX
| $17.1M | 0.94% | 1,182,563 | – | – |
|